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Till Tove och Wilhelm 
 
 
 
 
 
 
 
 
 
"Change is the essential process of all existence"  
   
Spock, Star Trek 
  
  
ABSTRACT   ENGLISH 
 
The overall aim of this thesis is to investigate drug use in institutionalized and home-
dwelling elderly, with a special focus on dementia. The major findings from the 
separate studies are summarized below. 
Study I. In this register-based study of 1 260 843 home-dwelling and 86 721 
institutionalized persons aged ≥65 years, 30% of the institutionalized and 12% of the 
home-dwelling elderly were exposed to potentially inappropriate drug use (PIDU). 
Institutionalization was associated with overall PIDU (OR 2.36, 95% CI 2.29-2.44), 
after adjustment for age, sex and number of drugs (i.e. a proxy for overall co-
morbidity).  
Study II. We studied the use of analgesics and psychotropics in 2 610 persons aged 
≥66 years who participated in the baseline examination in the Swedish National Study 
on Aging and Care-Kungsholmen (SNAC-K). About 46% of the persons with dementia 
and 25% of those without dementia used analgesics. Also, 63% of the persons with 
dementia compared to 32% of those without dementia used psychotropics. The 
prevalence of pain-related diagnoses was similar in persons with and without dementia. 
However, having a pain-related diagnosis was associated with use of psychotropics in 
persons with dementia, but not in those without dementia. 
Study III. In this study based on data from SNAC-K and the National Patient Register, 
persons with dementia had a higher prevalence of osteoporotic fractures in the previous 
four years than persons without dementia (i.e. 25% compared to 7%). Persons with 
dementia were, however, less likely to use osteoporosis drugs (OR 0.34, 95% CI 0.19-
0.59), after controlling for age, sex, osteoporotic fractures and type of housing (own 
home or institution).  
Study IV. In this nationwide register-based study, we analyzed use of antibiotics 
commonly used to treat lower urinary tract infection (UTI). We found that use of 
trimethoprim in institutionalized women was more than twice as common as the 
recommended level. Also, the use of quinolones, in women treated with UTI 
antibiotics, was high in women aged 65-79 years (i.e. used by 20% and 21% of 
institutionalized and home-dwelling women, respectively), which is not in line with the 
national recommendations. In men, we found that institutionalized men aged ≥80 years 
were less commonly treated with the recommended drugs (i.e. quinolones and 
trimethoprim) compared to home-dwelling men in the same age group (74% compared 
to 83%).  
Conclusions: Our results indicate that 1) institutionalization is a potential risk factor 
for PIDU, 2) although persons with dementia do not receive less analgesics than 
persons without dementia, they may be inappropriately treated with psychotropics for 
their pain, 3) persons with dementia are undertreated for osteoporosis, and 4) the 
treatment recommendations for lower UTI are not adequately followed. In order to 
improve the quality of drug therapy in older people, time and resources should be 
allocated to facilitate the implementation of regular medication reviews in this 
population and the cooperation between different health care professionals should be 
encouraged.  
  
SAMMANFATTNING    SVENSKA 
 
Det övergripande syftet med det här doktorandprojektet är att studera 
läkemedelsanvändning hos äldre personer i ordinärt och särskilt boende (SÄBO), med 
särskilt fokus på demens. En kort summering av de viktigaste resultaten från de 
ingående delstudierna ges nedan. 
Studie I. I denna registerbaserade studie av 1 260 843 hemmaboende och 86 721 
personer i SÄBO ≥65 år, fann vi att 30% av personerna i SÄBO och 12% i ordinärt 
boende var exponerade för potentiellt olämplig läkemedelsanvändning. Att bo i 
SÄBO var associerat med en ökad total risk för olämplig läkemedelsanvändning (OR 
2.36, 95% CI 2.29-2.44), även när vi justerat analyserna för ålder, kön och antal 
läkemedel (användes som en proxy för sjuklighet).  
Studie II. Vi studerade användningen av analgetika (smärtstillande läkemedel) och 
psykofarmaka hos 2 610 personer (≥66 år) som deltog i the Swedish National Study 
on Aging and Care-Kungsholmen (SNAC-K). Vi fann att 46% av personerna med 
demens och 25% av övriga deltagare använde analgetika. Vidare använde 63% av 
personerna med demens psykofarmaka jämfört med 32% av personerna utan demens. 
Det var ingen skillnad i förekomst av smärtrelaterade diagnoser. Att ha en 
smärtrelaterad diagnos var associerat med användning av psykofarmaka hos personer 
med demenssjukdom, men inte hos dem utan demens. 
Studie III. I denna studie baserad på data från SNAC-K och patientregistret, hade 
personer med demens fler osteoporosrelaterade frakturer de föregående fyra åren än 
personer utan demens (dvs. 25% jämfört med 7%). Trots detta hade personer med 
demens en lägre sannolikhet att få behandling med osteoporosläkemedel (OR 0.34, 
95% CI 0.19-0.59), när vi justerat analyserna för ålder, kön, osteoporosrelaterade 
frakturer och typ av boende.  
Studie IV. I denna registerbaserade studie, analyserade vi användningen av 
antibiotika som används för att behandla nedre urinvägsinfektion (UVI). Vi fann att 
kvinnor i SÄBO använde mer än dubbelt så mycket trimetoprim som den 
rekommenderade nivån. Vi fann också att yngre kvinnor (65-79 år) som behandlades 
med UVI-antibiotika ofta använde kinoloner (dvs. 20% och 21% av kvinnorna i 
SÄBO respektive eget boende), vilket inte stämmer överens med de nationella 
rekommendationerna. Hos män fann vi att de i SÄBO (≥80 år) mer sällan fick de 
rekommenderade läkemedlen för UTI (dvs. för män trimetoprim eller kinoloner) 
jämfört med hemmaboende män i samma ålder (dvs. 74% jämfört med 83%).  
Slutsatser: Våra resultat tyder på att 1) att bo i SÄBO är en möjlig riskfaktor för 
olämplig läkemedelsanvändning, 2) att personer med demens visserligen inte får 
analgetika i mindre omfattning än andra äldre, men att deras smärta riskerar att bli 
olämpligt behandlad med psykofarmaka, 3) att personer med demens är 
underbehandlade för osteoporos, och 4) att behandlingsrekommendationerna för 
behandling av nedre UVI inte följs i sin helhet. För att förbättra 
läkemedelsanvändningen hos äldre måste tid och resurser avsättas för att möjliggöra 
genomförandet av regelbundna läkemedelsgenomgångar. Även samarbetet mellan olika 
professioner inom vården bör uppmuntras. 
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1 INTRODUCTION 
 
1.1 DRUGS AND AGING 
 
1.1.1 Drug utilization in the elderly population 
The percentage of elderly people is increasing in the world. Increased life expectancy 
together with lower birth rates leads to this demographic change, which is expected to 
continue (Figure 1).
1
 
 
 
Figure 1. Proportion of the world population, 60 years and older year 1950-2050. 
Source: United Nations, World population aging 2009. Reprinted with permission. 
 
In Sweden, 18% of the population was 65 years and older in 2010.
2
 According to 
Statistics Sweden, life expectancy was 83 years for girls and 79 years for boys born in 
2010.
2
 One important factor for the increased life expectancy is that many diseases are 
today treatable with pharmacological drugs. Thus, many elderly persons live with 
multiple diseases and medications. In Sweden, people 75 years and older consume on 
average 5.4 prescription drugs per person.
3
 This corresponds to more than one fourth of 
all prescription drugs used in Sweden.
4-5
 Moreover, drug use in the elderly population 
has increased over time.
6-7
 
 
Drug therapy in the elderly population is complicated by age-related changes in the 
body (see the sections below about pharmacokinetics and pharmacodynamics), which 
make older people more sensitive to drugs than younger people. Also, use of many 
drugs simultaneously, i.e. polypharmacy, is associated with several adverse outcomes, 
such as increased risk of adverse drug reactions,
8
 inappropriate drug use
3
 and drug-drug 
interactions,
8-9
 which may cause hospitalizations.
10-11
 Taken together, older people have 
the greatest risks of adverse outcomes of drugs. 
 
Although elderly people on average consume many drugs, some conditions may be 
undertreated, e.g. osteoporosis, pain, depression and cardiovascular diseases.
12-15
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Therefore, continuous monitoring of elderly persons’ health and drug therapy is 
essential in order to optimize drug treatment and improve health status and quality of 
life. 
 
1.1.2 Age-related changes in pharmacokinetics 
Pharmacokinetics is often described as “what the body does to the drug”. It includes 
absorption, distribution, metabolism and excretion of the drug.
16
 Below are examples of 
age-related changes in the body which may affect the pharmacokinetics of drugs. The 
result is often a prolonged action and increased effects of the drug. 
 
1.1.2.1 Absorption 
The absorption of most drugs is not affected by old age per se. However, some 
diseases, surgery or use of certain drugs (i.e. opioids and anticholinergic drugs) may 
delay the absorption.
17
 
 
1.1.2.2 Distribution 
The relation between body fat and water changes in older people since the total amount 
of body water decrease.
18
 Therefore, fat-soluble drugs (e.g. the benzodiazepine 
diazepam), have a larger volume of distribution, which may lead to prolonged effect 
and accumulation of the drug which may in turn cause adverse side effects (e.g. 
excessive sedation).
17, 19
 
 
1.1.2.3 Metabolism 
The function of several liver enzyme systems is reduced in elderly people.
20
 This 
affects both the bioavailability (the fraction of the actual dose of the drug that reaches 
the bloodstream) and elimination of some drugs. 
 
Reduced function of enzymes involved in the first-pass metabolism may lead to an 
increased effect of certain drugs (e.g. propranolol) due to increased bioavailability.
21
 
Conversely, some drugs that are pro-drugs (i.e. drugs that are administered in an 
inactive form but are metabolized into an active form in the body) and activated via 
first pass-metabolism, e.g. enalapril, may have a decreased effect.
22
 
 
Fat-soluble drugs, in particular, undergo hepatic metabolism. Some of these drugs are 
eliminated slower in old age, e.g. diazepam, whereas the elimination of oxazepam is 
unchanged. Examples of other drugs that undergo hepatic metabolism, and may be 
eliminated slower in older people, are tramadol, citalopram and propranolol.
22-23
 
 
1.1.2.4 Excretion 
The most important age-dependent change in pharmacokinetics is the reduced renal 
function. As a consequence, water soluble drugs or metabolites, which undergo renal 
excretion, may be accumulated. This may lead to increased plasma concentrations and 
an increased risk for adverse side effects. Therefore, it is important to measure renal 
function in older people. Examples of drugs that need to be dose-adjusted according to 
renal function are atenolol, quinolones, digoxin and gabapentin.
23-25
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1.1.3 Age-related changes in pharmacodynamics 
Pharmacodynamics is often describes as “what the drug does to the body”.16 Several 
organ systems are changed in old age which may increase the risk for adverse effects of 
many drugs. Below are examples of important organ systems that may change with 
age.  
 
First, the brain becomes more sensitive to adverse side effects of many drugs that act on 
the central nervous system. This can lead to an increased sensitivity to sedative drugs.
19
 
Opioids may cause confusion and are associated with an increased risk of falls in 
elderly people.
26
 Due to changes in the central cholinergic pathways, older people are 
also particularly sensitive to anticholinergic drugs that may cause cognitive impairment 
and confusion in this population.
27
  
 
Second, the function of the baroreflex may be impaired. This can lead to an increased 
sensitivity of blood pressure lowering drugs and orthostatic reactions.
17
  
 
Third, the gastrointestinal mucosa becomes more sensitive with aging, which leads to 
an increased risk of non-steroidal anti-inflammatory drug (NSAID)-induced 
gastrointestinal bleeding.
28
  
 
1.1.4 Polypharmacy 
There are several definitions of polypharmacy. Some researchers have used a 
qualitative measure, such as use of drugs that are not clinically indicated.
10
 Others have 
defined polypharmacy quantitatively and a common definition is the use of five or 
more drugs.
29
 Over 60% of Swedes aged 70-79 years are exposed to polypharmacy 
according to that definition, and the prevalence of polypharmacy increases further with 
age.
30
 Polypharmacy has been associated with increased risk of adverse side effects, 
drug-drug interactions, hospitalization, medication errors, inappropriate drug use and 
decreased compliance.
3, 31
 Polypharmacy also leads to increased healthcare costs.
32
 
There is a linear relationship between number of used drugs and drug related problems 
(e.g. inappropriate drug use).
33
  
 
However, polypharmacy does not necessarily lead to adverse outcomes.
34
 It is possible 
to maintain a high quality even when the patient uses several drugs if there is a 
continuous monitoring of the drug therapy. The challenge is to recognize problems 
related to polypharmacy without denying elderly people valuable drug therapy.  
 
1.1.5 Geriatric pharmacoepidemiology 
1.1.5.1 Definition 
Epidemiology has been described as “the study of the determinants, occurrence, and 
distribution of health and disease in a defined population”.35 In pharmacoepidemiology, 
the outcome measure is usually drug use or an effect/consequence of drug use. 
Pharmacoepidemiology has been defined as the study of drug use in large populations 
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in order to promote a rational, safe and cost-effective use of drugs.
36
 In geriatric 
pharmacoepidemiology, the study population consists of elderly people. 
 
1.1.5.2 Geriatric pharmacoepidemiology in Sweden 
Sweden has a long tradition of collecting individual based health care information, 
including information about drug use. Drug use information has been collected in 
several population-based studies of elderly persons in Sweden. Information about all 
dispensed prescribed drugs is also collected in the nationwide Swedish Prescribed Drug 
Register (SDPR). Due to the unique personal identification number of each citizen in 
Sweden, it is possible to record link data about drug use to other registers, e.g. other 
health registers at the National Board of Health and Welfare (Table 1) or registers kept 
by Statistics Sweden, such as the Integrated Database for Labor Market Research 
(LISA), which includes information about, for example, education and proffession.
37
  
 
1.1.5.3 The Swedish Prescribed Drug Register  
During the recent years, many pharmacoepidemiological studies in Sweden have been 
based on the SPDR. The register contains, since July 2005, individual based 
information on all prescription drugs dispensed at Swedish pharmacies to the entire 
Swedish population (about 9 million inhabitants).
38
 The register contains information 
primarily about age, sex and dispensed drugs (i.e. amount of prescribed drugs, when the 
prescription was filled and prescribed dosage), costs, place of residence and data about 
the prescriber (e.g. profession).
38
 The Pharmacies Service Company (Apotekens 
Service AB) is responsible for administer the data collection which is mandatory for 
each pharmacy. The data is then transferred to the Swedish National Board of Health 
and Welfare, which is hosting the SPDR. The register is updated monthly. Only few 
other European countries, e.g. the Nordic countries
39
 and the Netherlands,
40
 have 
similar possibilities of studying individual-based drug use on a national level. Studying 
drug use in a large nationwide population has many advantages, including analysis of 
rare outcomes and exposures, such as individual drugs, and subpopulations (e.g. 
centenarians
41
) with high statistical precision. 
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Table 1. A selection of Swedish registers of health and social services at the Swedish 
National Board of Health and Welfare 
Register Year Main information 
The Swedish Prescribed 
Drug Register 
2002/ 
2005 
Information about prescribed drugs dispensed at 
pharmacies. Since 2005, the register contains individual- 
based information, such as age, sex and personal 
identification number. 
The National Patient 
Register 
1987 Information about all inpatient care for Sweden since 
1987 (for parts of Sweden since 1964). Since 2001, the 
register also contains information about specialized out-
patient care. 
The Swedish Medical Birth 
Register 
1973 Information about all births in Sweden. It is compulsory 
for each health care provider to report births to the 
register. 
The Swedish Cancer 
Register 
1958 Covers the whole Swedish population. It is mandatory 
for all health care providers to report all newly 
diagnosed cancers to the register. 
The Cause of Death Register 1961 Contains information about all deaths of people who are 
registered in Sweden. 
The Social Service Register 2007 All municipalities in Sweden report individual-based 
information about social services granted by the 
municipality to the register, including institutional care 
for elderly people. 
 
1.1.5.4 The Kungsholmen study and SNAC-K 
Many Swedish studies on drug use in the elderly have been based on data from the 
Kungsholmen project.
27, 42-49
 The Kungsholmen project was conducted in 
Kungsholmen, which is a central part of Stockholm, the capital of Sweden, between 
year 1987-2000. The main aim of the project was to study aging and dementia, but 
numerous studies were also published about other health related topics in the elderly.
50
 
 
In 1999, a longitudinal research project named The Swedish National Study on Aging 
and Care (SNAC) was initiated, aimed to study health and care in the aging population. 
SNAC consists of 4 research centers in different parts of Sweden. One of the research 
centers is Kungsholmen, Stockholm (SNAC-K). Similar to the Kungsholmen project, 
researchers from the Stockholm Gerontology Research Center and Aging Research 
Center, Karolinska Institutet, are responsible for the project. SNAC-K consists of a 
population-based part and a care system part.
51
 SNAC-K is an ongoing longitudinal 
project. In the population-based part, information about for instance drug use, diseases, 
cognition and socio-demographics are collected, which makes SNAC-K suitable for 
studies of drug use in the elderly population.  
 
1.1.6 Dementia 
Dementia leads to a decline in cognitive functions, e.g. memory and other intellectual 
abilities.
52
 According to the WHO, the symptoms of dementia can include: ”memory 
loss, difficulties with language, judgment, and insight, failure to recognize people, 
disorientation, mood changes, hallucinations, delusions, and the gradual loss of ability 
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to perform all tasks of daily living”.53 The personality and the emotional functions may 
also be affected.
52
 Dementia is uncommon below the age of 60, but after the age of 65, 
both the prevalence and incidence doubles every five years.
54
 In Sweden, more than 
140 000 persons have a dementia disorder.
55
 Institutionalization is common as the 
dementia disease progresses. As the main risk factor for dementia is old age, the 
number of persons with dementia is expected to increase in the future due to the 
increased life expectancy.
56
 The most common type of dementia is Alzheimer’s disease 
(AD), which accounts for about 60% of the dementia cases.
54
  
 
Persons with dementia are at particular risk of drug related problems. First, persons 
with dementia use more psychotropic drugs than other elderly persons.
44, 57
 This may be 
problematic since these persons are sensitive to adverse side effects of these drugs, such 
as confusion and falls.
58
 Second, persons with dementia are particularly sensitive to 
adverse side effects of drugs with anticholinergic properties (e.g. antipsychotics, 
tricyclic antidepressants and urinary antispasmodics). These drugs may affect cognitive 
functions negatively in persons with dementia.
59
 Third, dementia patients may be 
undertreated for several conditions, such as pain, osteoporosis and cardiovascular 
diseases,
 60-66
 because these patients often have difficulties in verbally communicating 
physical discomfort or pain.
52, 67
 Instead they may show behavioral symptoms, such as 
increased agitation, aggression, depression and anxiety.
68-69
 These behavioral 
symptoms can be misunderstood, which may lead to undertreatment of the somatic 
disorder or inappropriate treatment with psychotropics.
52, 70-71
  
 
1.2 DRUG USE AND TYPE OF HOUSING 
 
1.2.1 Institutions 
In Sweden, about 6% of persons aged 65 years and older live in different types of 
institutions,
72
 i.e. old people’s homes, group dwelling (small housing collectives where 
the residents have their own apartment but also have access to shared spaces, care and 
supervision),
73
 nursing homes and sheltered accommodations. Some settings are 
specialized in care for persons with dementia, i.e. special care units for dementia.
57
 
Although some institutions in Sweden are organized in private regime, almost all public 
elderly care is financed and organized within the municipality system.  
 
About 80% of the institutionalized elderly in Sweden have some degree of cognitive 
impairment and 60% have dementia.
55, 74
 In addition, institutionalized elderly often 
suffer from other diseases/conditions. Functional dependence, dementia, 
cerebrovascular disease and hip fractures have been associated with living in an 
institution.
75
 It has also been shown that institutionalized elderly more commonly suffer 
from physical disabilities, urinary incontinence, anxiety and depressive symptoms 
compared to home-dwelling elderly.
74
 
 
Drug use in institutions is often extensive and use of 10 or more different drugs is 
common.
76-78
 Co-morbidities and polypharmacy are factors that complicate drug use in 
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this population of frail, vulnerable persons. Bergman et al
78
 have showed that 70% of 
the elderly in these settings are exposed to potentially inappropriate drug use (PIDU).  
 
1.2.2 Home-dwelling elderly 
Home-dwelling elderly is a heterogeneous group of people. It includes both newly 
retired or still working healthy persons and elderly persons with multimorbidity with a 
great need for home-care services (e.g. assistance with households’ tasks, personal 
hygiene and help with administration of their medications). It has been estimated that 
home-dwelling elderly persons in Sweden use on average 4.3 drugs per person.
79
 
However, use of 10 different drugs and low quality of drug therapy are also common 
among home-dwelling elderly.
4
 Concerns have been raised about inappropriate drug 
use in this setting because drug therapy among home-dwelling elderly is usually less 
well monitored than among institutionalized elderly.
80
 
 
1.2.3 Comparing institutionalized and home-dwelling elderly  
Few previous studies have compared drug use between institutionalized and home-
dwelling elderly. However, Jyrrkä et al
6
 followed a random sample of elderly people 
aged 75 years and older in Kuopio, Finland, from 1998 to 2003. In 2003, 
institutionalized elderly used on average 11 drugs per persons compared to 7.5 among 
home-dwellers.
6
 The three most commonly used drug classes in home-dwelling elderly 
were then antithrombotic agents, cardiac therapy and beta blocking agents (used by 68, 
57 and 53%, respectively), whereas psycholeptics, analgesics and laxatives were the 
three most commonly used drugs classes in institutions (used by 86, 76 and 60%, 
respectively).
6
 The institutionalized elderly often suffered from multimorbidity, 
dementia and cardiovascular diseases in the Finnish study, which has also been found 
for Swedish institutions.
75
 Many patients were bedpatients, which may explain the high 
use of laxatives. However, the authors also discuss that the use of laxatives for 
constipation could be caused by side effects of anticholinergic drugs.
6
  
 
Table 2 shows the 20 most commonly dispensed drug classes in institutionalized and 
home-dwelling elderly according to a recent study by Johnell et al (in press). In this 
study, the three most commonly used drug classes among home-dwelling elderly were 
antithrombotic agents, beta blocking agents and lipid modifying agents, whereas the 
institutionalized elderly most frequently used antithrombotic agents, minor analgesics 
and antidepressants. This study was based on the same database as Study I and IV in 
this thesis. Although there are different disease patterns between institutionalized and 
home-dwelling elderly, other factors, such as different prescribing traditions in the two 
settings, may also play a role in explaining the differences in drug therapy. Further, as 
discussed by Johnell et al (in press), the high use of psychotropics in institutions may 
reflect an attempt to manage Behavioral and Psychological Symptoms of Dementia 
(BPSD) instead of using non-pharmacological methods, e.g. due to lack of staffing.  
 8 
 
                                                 
1
 The table is reproduced from Johnell K, Fastbom J. Comparison of drug use between community-
dwelling and institutionalised elderly. A nationwide study. Drugs & Aging: 2012, in press, with 
permission from Adis, a Springer business (© Adis Data Information BV 2012. All rights reserved). 
Table 2. The 20 most commonly dispensed drug classes in 1 347 564 persons aged 
 >65 years by residential setting, 2008, according to Johnell et al (paper in press)
1
 
Values are % (n).  
ATC-
code 
 
Community-
dwelling Institutionalized 
Drug class (n=1 260 843) (n=86 721) 
B01A Antithrombotic agents 36.6 (461 049) 48.3 (41 853) 
C07A Beta blocking agents 33.2 (418 905) 28.1 (24 411) 
C10A Lipid modifying agents 25.8 (324 942) 9.0 (7 800) 
C09A ACE inhibitors 16.2 (204 751) 14.6 (12 679) 
C08C Selective calcium channel blockers, mainly 
vascular effects  
16.6 (208 964) 9.7 (8 448) 
N05C Hypnotics/sedatives 14.6 (183 472) 33.8 (29 286) 
C03C High-ceiling diuretics 13.4 (168 798) 38.4 (33 260) 
N02B Minor analgesics 11.8 (149 000) 46.5 (40 296) 
A02B Drugs for peptic ulcer and gastro-
oesophageal reflux 
13.0 (163 996) 23.9 (20 746) 
B03B Vitamin B12 and folic acid 11.2 (140 705) 29.6 (25 712) 
N06A Antidepressants 10.1 (127 676) 43.9 (38 074) 
H03A Thyroid preparations 9.1 (114 951) 11.5 (9 977) 
C09C Angiotensin II antagonists 9.2 (116 110) 4.5 (3 937) 
A12A Calcium 7.7 (96 907) 12.5 (10 815) 
A06A Laxatives 6.2 (77 787) 33.9 (29 374) 
A10B Blood glucose lowering drugs, excl. 
insulins  
8.0 (100 606) 7.0 (6 061) 
M01A Non-steroid antiinflammatory and 
antirheumatic products  
8.1 (102 687) 3.7 (3 206) 
N02A Opioids 6.7 (84 032) 17.9 (15 484) 
G03C Estrogens 7.3 (91 844) 8.1 (7 065) 
C03A Thiazide diuretics 7.5 (94 457) 4.6 (3 947) 
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1.3  POTENTIALLY INAPPROPRIATE DRUG USE 
 
1.3.1 Definition 
Potentially inappropriate drug use (PIDU) has been defined as use of medications for 
which the risks outweigh the benefits.
81
 PIDU in the elderly population can be use of 
drugs that due to age-related changes are less well tolerated than in younger people. 
PIDU also includes the use of drugs with wrong dosages or duration for the 
indication
82-83
 or use of drugs without evidence-based indication.
84
 Also, 
undertreatment of potentially treatable diseases is a form of PIDU.
84
 
 
Many adverse drugs reactions in elderly people are caused by poor prescribing and are 
at least partly preventable by better knowledge and practice.
85
 
 
1.3.2 Occurrence and consequences 
PIDU is a common health problem in the elderly population. Studies of PIDU have 
reported prevalences between 3-70% in older people.
3, 29, 78, 86-90
 The wide range is 
explained by the use of different criteria for the definition of PIDU and different 
settings. The lowest prevalence has been found among elderly in ambulatory care
81
 and 
the highest in institutions.
78
 Table 3 shows important studies of PIDU published in the 
previous 10 years. 
 
PIDU has been associated with adverse drug reactions, hospitalization, admittance to 
nursing home and mortality.
91-94
 There is also a risk that side effects caused by PIDU 
are misinterpreted as disease symptoms and treated with additional drugs, which leads 
to a “prescribing cascade” with possible harmful consequences.95 
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Table 3. A selection of important studies of PIDU in institutionalized and home-dwelling elderly published in the past 10 years. 
Author, year Participants Measure of PIDU Main finding 
Leikola et al. 
2011
96
 
N=841 509, age: ≥65 years, register-based Finnish 
study of non-institutionalized elderly, year: 2007. 
Modified Beers 2003 criteria
97
 Prevalence of PIDU was 14.7% in home-
dwelling elderly. 
Barnett et al. 
2011
98
 
N=70 299, age: 66-99 years, institutionalized and 
home-dwelling elderly residing in Tayside, Scotland, 
year: 2005-2006. 
Modified Beers criteria 2003
97
 Prevalence of PIDU was 31%. No overall 
association between institutionalization and 
PIDU was found. 
Ghadimi et al. 
2011
99
 
N=2 041, age: ≥65 years, older persons visiting the 
General Practitioner, Iran, year: 2005 and 2006. 
Modified Beers 2003
97
 Prevalence of PIDU was 30%. 
Ruggiero et al. 
2010
100
 
N=1 716, age: ≥65 years, nursing home residents, 
ULISSE project, Italy, year: 2004-2005 
Modified Beers 2003
97
 Prevalence of PIDU was 48%. 
Cahir et al. 
2010
101
 
N=338 801, age: ≥70 years, national population study, 
Ireland, year: 2007 
European criteria
102
  Prevalence of PIDU was 36%. 
Hosia-Randell 
et al. 2008
103
 
N=1 987, age ≥65 years, institutionalized elderly, 
Helsinki, Finland, year: 2003. 
Modified Beers 2003
97
 Prevalence of PIDU was 34.9%. 
Johnell et al. 
2007
3
 
N=732 228, age: ≥75 years, register-based nationwide 
study, Sweden, year: 2005. 
National indicators for rational drug use in 
the elderly population
104
 
Prevalence of PIDU was 17% (both 
institutionalized and home-dwelling elderly 
included).  
Bergman et al. 
2007
78
 
N=7 904, age: ≥65 years, multi-dose users residing in 
nursing homes, Gothenburg, Sweden, year: 2003. 
National indicators for rational drug use in 
the elderly population
104
 
Prevalence of PIDU in nursing homes was 
74%. 
Goulding et al. 
2004
105
 
N=22 031, age: ≥65 years, ambulatory care, U.S. year: 
1995 and 2000.  
Beers 1997 criteria
106
 Prevalence of PIDU in ambulatory care was 
7.8% in both 1995 and 2000. 
Lane et al. 
2004
107
 
N=1 275 619, age ≥66 years, home-dwelling and 
institutionalized elderly, Ontario, Canada, year: 2001. 
Modified Beers, potentially inappropriate 
drugs in the always avoid or rarely 
appropriate category were studied
108
 
The prevalence of PIDU was 2.3% in 
institutionalized elderly and 3.3% in home-
dwelling elderly. 
Dhalla et al. 
2002
80
 
N=19 911, age: ≥66 years, persons newly admitted to 
nursing homes, Ontario, Canada, year: 1997- 1999. 
Modified Beers criteria, a subset
106
 The prevalence of PIDU declined from 25.4% 
to 20.8% after nursing home admission. 
1
0
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1.3.3 Measures of inappropriate drug use 
1.3.3.1 Beers criteria (United States) 
The most commonly used measure of PIDU in the elderly population is probably the 
Beers criteria, which were originally developed in the United States in 1991 for use in 
the nursing home setting.
109
 The Beers criteria have been continuously updated and the 
later versions are more applicable also for home-dwelling elderly persons.
97, 106
 The 
version from 2003 includes 48 individual drugs or classes of drugs considered as 
inappropriate to use in older people.
97
 In addition, it includes drugs that should be 
avoided in 20 diseases/conditions.
97
 Some of the drugs in the Beers criteria are 
dependent on the prescribed dosage. The Beers criteria, including modified versions, 
have been widely used in studies of PIDU in both the U.S. and in Europe.
80-81, 98, 103, 105, 
107, 110-112
 However, since these criteria were developed for use in the U.S., they are not 
a completely accurate measure when applied to data from other countries. For instance, 
several drugs that are approved in the U.S. are not available in European countries. In 
addition, DDIs are not included in the Beers criteria.
101
 The Beers full list of criteria has 
also been criticized for being a too rough measure in a recent study that found no 
significant impact on mortality in patients exposed to PIDU, as defined by the Beers 
criteria, compared to non-exposed elderly persons.
98
 
 
1.3.3.2 STOPP/START (Europe) 
In order to create a measure of inappropriate drug use more suitable for the European 
situation, the STOPP/START criteria were developed by experts in Ireland and the 
United Kingdom in 2008. The STOPP (Screening Tool of Older Persons potentially 
inappropriate Prescriptions) criteria contain 65 criteria for inappropriate prescribing in 
elderly people and the START (Screening Tool to Alert doctors to Right Treatment) 
criteria contains 22 prescribing indicators for common diseases in older people.
102
  
 
1.3.3.3 National indicators 
Several countries, such as Sweden, Norway, Finland and France, have developed 
national indicators for evaluation of the quality of drug therapy in older people.
83, 104, 
113-115
 An advantage is that such indicators may be a more appropriate measure of PIDU 
since they are developed for national conditions. 
 
In Sweden, the National Board of Health and Welfare has developed both disease- and 
drug specific indicators for evaluation of the quality of drug therapy in older people. 
The first version was launched in 2003 and a revised version in 2010.
83, 104
 Several of 
the drug-specific indicators have successfully been applied to register-based data, i.e. 
use of anticholinergic drugs, long-acting benzodiazepines, concurrent use of three or 
more psychotropics and potentially serious drug-drug interactions (DDIs).
3, 29, 87-88
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1.4 TREATMENT OF SOME COMMON CONDITIONS IN THE ELDERLY 
 
1.4.1 Pain 
Pain is common in the elderly population. It has been estimated that about 50% of 
home-dwelling elderly and up to 80% of nursing home residents suffer from pain.
13
 In 
the elderly population, chronic pain is often experienced in major joints, the back, legs 
and feet, and underlying diseases are often osteoarthritis, fractures and cancer.
116
 
 
Several previous studies have reported an undertreatment of pain in the elderly. For 
instance, a recent U.S. study of 14 017 nursing home residents found that 44% of the 
residents with pain did not receive standing orders for pain medication or appropriate 
pain management.
117
 Several reasons for the undertreatment have been suggested, e.g. 
fear of adverse side effects of analgesics, polypharmacy and communication problems 
between the patients and the health care staff.
118
 
 
Cognitive impairment is probably the major reason for communication problems, 
which may lead to undertreatment of pain. Numerous studies have shown that persons 
with dementia receive less pain treatment than other elderly, although some recent 
studies have not found that persons with dementia receive fewer analgesics (Table 4). 
Unrelieved pain may have severe consequences in everyday function and quality of life 
and may lead to increased agitation, depression and anxiety in older people.
119-122
 
 
There are several pain-assessment tools available for assessment of pain in patients 
with dementia.
123
 In patients with mild dementia, self-report may be an adequate 
measure of pain. For patients with more severe dementia, however, it is more suitable 
to use a behavior-observation tool. For instance, Horgas et al
124
 showed that persons 
with dementia self-reported less pain compared to cognitively intact persons, but they 
found no difference in behavioral pain indicators. 
 
1.4.1.1 Pain medications 
Analgesics are usually divided into peripherally acting (paracetamol, acetylsalicylic 
acid and NSAIDs) and centrally acting (e.g. opiods). Mild to moderate pain can usually 
be treated successfully with paracetamol (acetaminophen). In more severe pain 
conditions, it can be combined with a minor opioid (codeine or tramadol) or a major 
opioid (e.g. morphine).
125
 NSAIDs are mainly used for treatment of inflammatory pain. 
 
Paracetamol is considered to be safe when used in recommended doses. NSAIDs need 
to be prescribed with caution in older patients since they can cause gastrointestinal and 
renal complications.
28, 126
 In addition, use of NSAIDs have been associated with 
increased risk of myocardial infarction and death.
127
 Opioids may cause constipation 
and sedation and have been associated with an increased risk of falls in older people.
26, 
125
 On the other hand, poorly treated pain has also been associated with increased risk 
of falls in elderly women.
128
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In neuropathic pain, which is a special form of pain caused by damages in the 
peripheral or central neurons, traditional analgesics are generally ineffective. Tricyclic 
antidepressants and anti-epileptic drugs may be used instead.
129
 
 
Table 4. A selection of important studies of pain treatment in older persons with 
dementia or cognitive impairment 
Author, 
year 
Study participants Main finding 
Horgas et al. 
2009
124
 
N=126, age: ≥65 years, 
institutionalized elderly 
in Florida, year: not 
specified 
Cognitively impaired elderly self-reported less 
movement-related pain, but there was no difference 
in pain behavioral indicators. Cognitively impaired 
elderly received on average 500 paracetamol 
equivalents more than cognitively intact elderly. 
Husebo et al. 
2008
60
 
N=181, age: ≥65 years, 
nursing home residents 
in Norway, year: not 
specified 
Patients with severe dementia and mixed dementia 
who were treated with opioids had a higher pain 
intensity score than persons without dementia who 
were treated with these drugs. 
Lövheim et 
al. 2008
130
 
 
N=546, age: ≥85 years, 
home-dwelling and 
institutionalized elderly, 
in northern Sweden and 
Finland, year: 2005-2006  
Persons with dementia received significantly more 
paracetamol. There was no difference in use of 
opioids or NSAIDs. 
Reynolds et 
al. 2008
62
 
N=551, age: range 22-
103 years, nursing home 
residents in North 
Carolina, U.S., year: 
2001-2004 
56% of the patients with severe cognitive 
impairment received analgesics compared to 85% 
of the cognitively intact. There was no difference in 
the presence of pain-related conditions. 
Nygaard et 
al. 2005
61
 
N=125, age: ≥65 years, 
nursing home residents 
in Norway, year: 2000-
2001 
Elderly with a dementia diagnosis were less likely 
to receive PRN analgesics, but there was no 
difference in use of scheduled medications.  
Balfour et al. 
2003
70
 
N=460, age: ≥65 years, 
institutionalized and 
home-dwelling 
Alzheimer patients in 
Canada, year: 1991 
Less than half of the arthritis patients received no 
pain treatment. Alzheimer patients with 
arthritis/rheumatoid arthritis received more 
benzodiazepines than the other Alzheimer patients. 
Morrison et 
al. 2000
63
 
N=98, age: ≥70 years, 
hip-fracture patients 
admitted to a U.S. 
hospital, year: 1996-
1998 
Hip-fracture patients with severe dementia received 
1/3 the amount of opioid analgesics than those 
without dementia. 
 
1.4.2 Osteoporosis 
Osteoporosis is a bone disease that is common in the elderly population. The bones 
become porous and the risk for fractures increases. Sweden has one of the highest 
prevalences of osteoporosis in the world and the occurrence increases with age.
131
 It has 
been estimated that about 50% of the institutionalized men and up to 85% of the 
institutionalized women have osteoporosis.
132-133
 A Swedish study has even suggested 
that almost all institutionalized women have osteoporosis.
134
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Osteoporosis causes approximately 70 000 fractures per year in Sweden.
135
 Common 
sites for osteoporotic fractures are the hip, spine and forearm.
136
 The lifetime risk for a 
fracture in one of these sites is 46% for a 50 year old Swedish woman.
136
 For a man, the 
risk is 22%.
136
 Hip fractures, one of the most severe consequences of osteoporosis, have 
been associated with increased morbidity and mortality.
131, 137
 
 
Several previous studies have reported an undertreatment of osteoporosis in older 
people, i.e. in the oldest old,
12
 in nursing homes,
138
 for prevention of a secondary 
osteoporotic fracture,
139-140
 among low educated elderly
141
 and in persons with 
dementia.
65
 
 
Persons with dementia are considered as a high risk group for osteoporotic fractures 
because dementia is associated with an increased risk of falls and hip fractures.
135, 142-143
 
 
1.4.2.1 Osteoporosis medications 
The Swedish Council of Health Technology Assessment (SBU) has concluded that 
enough evidence is available to support use of calcium/vitamin D combinations, 
bisphosphonates and raloxifene in order to prevent osteoporotic fractures in older 
people.
135
 
 
Bisphosphonates and raloxifene are antiresorptive drugs that increase the bone strength. 
Raloxifene is a selective estrogen receptor modulator that is approved for use in post-
menopausal women.
135, 144
  
 
Calcium/vitamin D combinations are considered as a less potent osteoporosis treatment, 
but may reduce the risk for hip- and other non-spinal fractures in the elderly.
135
 
 
1.4.3 Urinary Tract Infection 
In institutions, urinary tract infection (UTI) is the most common indication for 
antibiotic prescriptions, accounting for up to 60% of such prescriptions in this 
setting.
145
 In home-dwelling elderly, it is the second most common infection.
146
 UTI is 
most common in women, but also fairly common in elderly men, as the prevalence 
increases with age.
147
 Concerns have been raised about the quality of use of UTI 
antibiotics in the institutional setting, as only 50% of the prescribed antibiotics are used 
according to recommendations.
148
 Less is known about the quality of use of these drugs 
among home-dwelling elderly. However, the Swedish recommendations has been 
reported to be inadequately followed in a study of women >18 years who visited 
primary health care.
149
 
 
The most common type of UTI is lower uncomplicated UTI (cystitis).
145
 Lower UTI 
is usually a harmless disease although it can be painful.
150
 There is a low risk that it 
progresses to pyelonephritis, a more severe disease where the kidneys are involved in 
the infection.
150
 Asymptomatic bacteriuria (ABU) is when bacteria are present in the 
urine but the patient has no clinical symptoms. Among the institutionalized elderly, 
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the prevalence of ABU is up to 50% in women and 40% in men.
151
 Treatment with 
antibiotics in ABU is not recommended, yet it occurs frequently.
151
 
 
1.4.3.1 Antibiotics 
1.4.3.1.1 Women 
New Swedish national guidelines for treatment of lower UTI in adult women were 
published in 2007 by the Swedish Medical Product Agency in collaboration with the 
Swedish strategic program against antibiotic resistance (STRAMA).
145
 According to 
these recommendations, pivmecillinam and nitrofurantoin should be considered as first 
line treatment. Due to increased resistance levels, trimethoprim is now considered as 
secondary choice and the use of quinolones should be minimized.
104, 145
 The treatment 
of lower UTI can be empirical, which means that no urine cultivation is necessary if the 
symptoms are typical.
145
  
 
Figure 2 shows the sales of the most commonly used UTI antibiotics in women year 
2000-2010. In recent years, the sales of trimethoprim and quinolones have decreased in 
favor for pivmecillinam and nitrofurantoin, as recommended by the national guidelines. 
 
 
Figure 2. Antibiotics commonly used to treat UTI in Swedish women year 2000-2010. 
Source: Swedish Institute for Communicable Disease Control, SWEDRES 2010. 
Reprinted with permission. 
 
 
1.4.3.1.2 Men 
The National Board of Health and Welfare has published indicators for treatment of 
UTI in elderly men.
104
 Since the prostate is often involved in the infection in men, the 
treatment recommendations for UTI differ from that in women. In men, quinolones or 
trimethoprim are recommended because these drugs penetrate prostatic tissue and 
secretions.  
 16 
 
1.4.3.2 Antibiotic resistance 
Antibiotic resistance is considered as a global health concern by the WHO.
152
 
Widespread use of antibiotics is a risk factor for antibiotic resistance.
153
 
Although Sweden has low resistance levels compared to other European countries, the 
problem is increasing.
154
 To keep the resistance levels as low as possible, it is important 
with continuous monitoring of the use of antibiotics and the actual situation of 
resistance. It is also important that national guidelines regarding antibiotic prescribing 
are continuously updated to guide the prescriber to choose antibiotics with a favorable 
resistance profile.  
 
The most common uro-pathogen is Eschericha Coli.
145
 The resistance levels varies 
between regions in Sweden, but is overall 1-3% for pivmecillinam and nitrofurantoin, 
which are the first line antibiotics.
145
 For trimethoprim, the resistance level has almost 
doubled since 1996, and is now about 19% in Escherichia Coli isolates.
154-156
 Also, the 
resistance levels for quinolones have increased in Sweden in recent years, from 8% in 
2002 to 13% in 2010.
156
 Figure 3 illustrates the resistance levels to quinolones in 
Sweden and in other European countries.  
 
 
Figure 3. Proportion of Quinolone resistant (R + I) Escherichia coli isolates in 
European countries 2010. Source: EARS-Net
2
 
                                                 
2
 Map generated by the European Antimicrobial Resistance Surveillance Network (EARS-Net) online 
database, European Centre for Disease Prevention and Control, 16 February 2012. 
http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/database/Pages/map_reports.aspx 
Reprinted with permission. 
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2 AIMS 
 
2.1 GENERAL AIM 
 
The general aim of this thesis is to investigate drug use in institutionalized and home-
dwelling elderly persons, with a special focus on dementia. 
 
2.2 SPECIFIC AIMS 
 
2.2.1 Study I 
The aim was to compare potentially inappropriate drug use (PIDU) in institutionalized 
versus home-dwelling elderly persons in Sweden.  
 
2.2.2 Study II 
The aim was to investigate if persons with dementia were as likely as persons without 
dementia to receive pharmacological pain treatment. We also aimed to investigate 
whether use of psychotropics was related to pain in persons with and without dementia. 
 
2.2.3 Study III 
The aim was to investigate and compare use of osteoporosis drugs among nursing 
home residents and home-dwelling elderly with and without dementia. 
 
2.2.4 Study IV 
The aim was to compare the quality and pattern of use of urinary tract infection (UTI) 
antibiotics (i.e. quinolones, pivmecillinam, trimethoprim and nitrofurantoin) between 
institutionalized and home-dwelling elderly persons.  
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3 MATERIALS AND METHODS 
 
3.1 DATA SOURCES 
 
3.1.1 The Swedish Prescribed Drug Register (Study I and IV)  
The SPDR contains, since July 2005, individual based information on all prescription 
drugs dispensed at Swedish pharmacies to the entire Swedish population (about 9 
million inhabitants).
38
 
 
3.1.1.1 Measurement of drug use (SPDR) 
We analyzed use of dispensed, prescribed drugs on the date of 30 September 2008 in   
1 260 843 home-dwelling and 86 721 institutionalized elderly persons. In Sweden, 
prescription drugs are prescribed for use for at most three months. Therefore, our 
computerized analyses employed an algorithm based on information about when the 
prescription was filled, the amount of drugs dispensed and the prescribed dosage, from 
the previous three-month period, to construct a list of concurrently used drugs on a 
given date, in this case September 30, 2008. When data on prescribed dosage were 
incomplete or missing (9.9%), the daily dose for the actual drug was looked up in a 
table derived from the same dataset with mean daily doses from prescriptions with 
known dosage information. For drugs prescribed as needed we assumed a dosage of 
50% of that for regular drugs. Moreover, we assumed a daily dose of 1 defined daily 
dose (DDD)
157
 for eye preparations and dermatological drugs.
3
 If the same drug was 
dispensed more than once during the period, it was counted as one drug.  
 
Information about over-the-counter (OTC) drugs, drugs used in hospitals and drugs 
supplied from drug store rooms in institutions are not included in the SPDR. 
 
3.1.2 The Swedish Social Services Register (Study I and IV) 
Since 2007, all municipalities in Sweden report individual-based information about 
granted institutional care and home-help for older people to the Swedish Social 
Services Register.
72
 We collected information from the register about type of housing 
(i.e. home dwelling/institution) on 30 June 2008. By that date, all Swedish 
municipalities had reported to the register.
72
 Only a small fraction of the institutional 
care is organized outside the municipality system in Sweden. 
 
3.1.3 The National Patient Register (Study III) 
The National Patient Register contains, since 1987, information about all hospital 
discharges for the entire Swedish population. The register was recently validated and, 
today, more than 99% of all somatic and psychiatric hospital discharges are recorded in 
the register.
158
 Since 2001, the register also contains information about specialized out-
patient care. 
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3.1.4 SNAC-K (Study II and III) 
 
3.1.4.1 Data collection 
SNAC-K is an ongoing longitudinal study. However, we used data from the baseline 
examination collected in 2001-2004. At baseline, each participant met a team 
consisting of a physician, a registered nurse and a psychologist, for interviews and 
examination.
51
 Data about pain, diseases and drug use were collected during the 
interview by the physician. The full protocol is available at www.snac-k.se. When the 
older person could not provide information, a relative was asked instead. However, 
relatives or caregivers were not asked about the participants’ experience of pain. If the 
person was living in an institution, the information was most often collected from 
medical records.  
 
3.1.4.2 Study population 
Study II and III are based on data from the population based part of the SNAC-K study. 
SNAC-K consists of a sample of older persons from different age cohorts (age 60, 66, 
72, 78, 81, 84, 87, 90, 93, 96, and 99 years and older), who live in Kungsholmen / 
Essingeöarna, a central part of Stockholm, the capital of Sweden.  
 
For the baseline examination, 5 111 persons were invited to participate and of these      
4 590 were alive and eligible for participation (200 dead, 262 not able to contact, 4 
deaf, 23 did not speak Swedish and 32 had moved), and of the eligible, 3 363 (73%) 
participated in the baseline examination. We only analyzed persons aged 66 years and 
older who had completed the interview with the physician (n=2 610). Of these, 305 had 
a dementia disorder. Five persons with missing information about drug use were 
excluded. 
 
3.1.4.3 Measurement of drug use (SNAC-K) 
In contrast to the SPDR, drug use in SNAC-K was based on self-report and included 
information about use of both prescribed and OTC drugs. During the baseline 
interview, the physician asked the participant about current drug use, including both 
regularly and as needed used drugs. Participants were asked in advance to bring a list of 
currently used drugs to the interview. If possible, e.g. when the interview was 
performed in the participant’s own home, also drug prescriptions and medical 
containers were inspected. If the participant resided in an institution, information about 
drugs was most often retrieved from medical records.  
 
The drug use analysis was performed by the custom designed software Monitor 
(Quality Pharma AB, Västerås, Sweden), which automatically classifies the drugs 
according to the Anatomical Therapeutic Chemical (ATC) classification system. 
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3.2 OUTCOME MEASURES AND EXPLANATORY VARIABLES 
 
3.2.1 Outcome variables 
All studies in this thesis have drug use as outcome variable. Drugs were classified 
according to the ATC classification system, as recommended by the WHO.
157
 
 
3.2.1.1 PIDU (Study I) 
The Swedish National Board of Health and Welfare has developed indicators for 
evaluation of the quality of drug therapy in older people.
104
 The indicators consist of 
both disease specific and drug-specific indicators. We analyzed four of the drug 
specific indicators, which have previously been applied to register-based data.
3, 78, 87
 
Table 5 shows the analyzed indicators with examples and possible consequences. 
 
 
Table 5. Indicators developed by the Swedish National Board of Health and Welfare in 
2010 for analyses of PIDU in elderly persons (Study I) 
Indicator Example of 
drug/combination 
May cause (examples) 
Use of anticholinergic 
drugs 
Antihistamines, urinary 
antispasmodics, older types 
of antipsychotics 
Cognitive impairment, 
confusion and impaired 
functional status
159-160
 
Long-acting 
benzodiazepines 
Diazepam, flunitrazepam, 
nitrazepam 
Excessive sedation, 
cognitive impairment and 
falls
83, 159
 
Concurrent use of 3 or 
more psychotropic drugs 
Antipsychotics, anxiolytics, 
hypnotics/sedatives and 
antidepressants 
Refined measure of 
polypharmacy, may cause 
cognitive side effects
161
 
Potentially serious drug-
drug interactions 
Concurrent use of aspirin and 
warfarin 
Attenuated/abolished 
therapeutic effects or 
severe side effects
162
 
 
3.2.1.2 Analgesics and psychotropics (Study II) 
We analyzed use of the following analgesics: any analgesic (ATC-code N02), 
paracetamol (N02BE01) and opioids (N02A). We also analyzed the use of NSAIDs 
(M01A), excluding glucosamine (M01AX05). Use of psychotropics was classified into 
use of at least one psychotropic drug (i.e. antipsychotics (N05A), anxiolytics (N05B), 
hypnotics and sedatives (N05C) or antidepressants (N06A)).  
 
3.2.1.3 Osteoporosis drugs (Study III) 
We analyzed use of the following osteoporosis drugs: calcium/vitamin D combinations 
(ATC-code A12AX), raloxifene (G03XC01) and bisphosphonates (M05BA and 
M05BB). We also analyzed the use of “any osteoporosis drug”, which referred to the 
use of at least one drug in the ATC-classes A12AX, G03XC01, M05BA or M05BB.  
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3.2.1.4 UTI antibiotics (Study IV) 
We investigated use of the following antibiotics commonly used for treatment of lower 
UTI:
163
 quinolones (ciprofloxacin (ATC-code J01MA02) and norfloxacin (J01MA06)), 
pivmecillinam (J01CA08), trimethoprim (J01EA01) and nitrofurantoin (J01XE01).  
 
The National Board of Health and Welfare has developed indicators for treatment of 
UTI in elderly women and men.
104
 We analyzed several of these indicators, which 
could be applied to register-based data. We also analyzed one of the quality indicators 
for treatment of lower UTI in adult women developed by The Swedish Association of 
General Practice:
150
 Women: 1) The proportion women treated with UTI antibiotics for 
lower UTI, who used quinolones (should be as low as possible);
104
 2) The proportion 
women treated with the recommended drugs, pivmecillinam, nitrofurantoin or 
trimethoprim (should be about 40%, 40% and 15-20%, respectively)
150
; Men: 1) The 
proportion men of all men treated with UTI antibiotics who used either quinolones or 
trimethoprim (should be as high as possible).
104
 
 
3.2.2 Main explanatory variables 
3.2.2.1 Type of housing  
Type of housing was classified into home-dwelling (living in own home) or 
institutionalized (e.g. sheltered accommodation, old people’s home, group dwelling or 
nursing home).
79, 164
 This definition was made because it is not possible to distinguish 
between different types of institutional care in the Social Services Register (Study I and 
IV).
72
 We therefore classified the type of housing variable in a similar way also in 
Study II and III, which are based on SNAC-K data. 
 
3.2.2.2 Dementia  
In SNAC-K (Study II and III), two physicians set the dementia diagnosis independent 
of each other according to the DSM-ІV criteria.165 In case of disagreement, a third 
expert was consulted to make the final diagnosis.
166
 Persons with questionable 
dementia (the criteria of memory impairment was fulfilled, whereas a second cognitive 
dysfunction was questionable) were included in the dementia group.
42
 
 
In study I and IV, we used treatment with anti-dementia drugs (ATC code N06D, i.e. 
cholinesterase inhibitors and memantine) as a proxy for dementia diagnosis.
101
  
  
3.2.2.3 Age 
Age was introduced in the statistical models as a continuous variable. We also 
performed analyses stratified into younger elderly (<80 years of age) and older elderly 
(≥80 years of age) in Study I, III and IV. 
 
3.2.2.4 Co-morbidities 
In Study I and IV, we used number of drugs (continuous variable) as a proxy for overall 
co-morbidity.
167
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In Study II, we constructed a dichotomous variable based on presence of pain-related 
diagnoses.
60-62
 We included the following diseases/conditions available in the SNAC-K 
questionnaire and commonly associated with pain: hip fracture the present or previous 
year, vertebral compression, rheumatic disorders (including rheumatoid arthritis, 
polymyalgia rheumatica, SLE and vasculitis,), osteoporosis, osteoarthritis, cancer the 
present or previous year and headache/migraine. 
 
In Study III, we analyzed the occurrence of osteoporotic fractures in the previous four 
years. Information about these fractures was obtained from the National Patient 
Register.
168
 We included the following fractures (with ICD-10 codes), commonly 
related to osteoporosis:
136, 169
 fractures of femur (S72), rib(s), sternum and thoracic 
spine (S22), lumbar spine and pelvis (S32), shoulder and upper arm (S42), forearm 
(S52) and lower leg, including ankle (S82). We also analyzed the occurrence of “any 
osteoporotic fracture”, defined as at least one of the above mentioned fractures.  
 
3.3 STATISTICAL ANALYSIS 
 
All statistical analysis was performed by using SPSS statistical packages, version 17.0 
or later (SPSS Inc., Chicago, IL, USA). 
 
3.3.1 Specific analysis 
3.3.1.1 Study I 
We performed crude and adjusted logistic regression analysis in order to study the 
association between institutionalization and PIDU. In the crude model, only type of 
housing was entered as explanatory variable. In model 1, adjustment was made for age 
(continuous variable) and sex. In model 2, additional adjustment was made for number 
of drugs (continuous variable) and the interactions between age and type of housing 
and between number of drugs and type of housing. We also made a separate analysis of 
younger elderly (<80 years of age) and older elderly (≥80 years of age). To study PIDU 
in persons with dementia, we used treatment with anti-dementia drugs (ATC code 
N06D, i.e. cholinesterase inhibitors and memantine) as a proxy for dementia 
diagnosis.
101
  
 
3.3.1.2 Study II 
We used logistic regression analysis to study the association between dementia status 
and use of analgesics and psychotropics in the study population. We used both crude 
and adjusted analysis. In model 1, adjustment was made for age (continuous variable) 
and sex. In model 2, additional adjustment was made for pain-related diagnosis and the 
interactions between sex and dementia, age and dementia, and pain-related diagnosis 
and dementia. In model 3, further adjustment was made for type of housing (own home 
or institution) and the interaction between pain-related diagnosis and type of housing. 
All variables involved in the interaction terms were effect-coded (also called deviance 
coding).
170
 Hence, all results obtained were for the average person. Second, we 
analyzed persons with and without dementia separately in order to investigate how the 
different explanatory variables were associated with the use of analgesics and 
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psychotropics. The Mini Mental State Examination (MMSE)
171
 was used to control for 
dementia severity. 
 
Exclusively for this thesis, we also made an analysis stratified by type of housing, to 
explore how dementia status and pain-related disorders were associated with use of 
analgesics and psychotropics in the different settings.  
 
3.3.1.3 Study III 
We used logistic regression analysis to investigate the association between dementia 
status and use of osteoporosis drugs. We used both crude and adjusted analysis. First, 
we analyzed the whole dataset. In model 1, adjustment was made for age (continuous 
variable) and sex. In model 2, additional adjustment was made for type of housing 
(own home or institution) and osteoporotic fractures. There was no interaction between 
dementia status and type of housing. Second, we excluded the severely demented cases, 
in order to investigate if our results were influenced by low use of osteoporosis drugs in 
patients with severe dementia. We used the MMSE
171
 as a measure of dementia 
severity and only included subjects with MMSE ≥10 in this analysis. 
 
3.3.1.4 Study IV 
We analyzed men and women separately. We also stratified the data into younger 
elderly (<80 years of age) and older elderly (≥80 years of age). Both crude and adjusted 
logistic regression analysis was used to study whether institutionalization was 
associated with use of UTI antibiotics. In the adjusted model, we controlled for age and 
number of other drugs (continuous variable). There were no significant interaction 
terms. Similar to Study I, we also studied the use of UTI antibiotics in persons who 
concurrently used anti-dementia drugs (ATC code N06D). 
 
3.3.1.5 Weighting the SNAC-K data (Study II and III) 
As the sampling fractions in the different age groups were different in SNAC-K, i.e. a 
proportionally larger group of the youngest and oldest age groups were sampled, data 
from the examined population was weighted against the total population in 
Kungsholmen / Essingeöarna by age group and sex. In Study II, we chose to present all 
figures and proportions weighted, whereas in Study III, we chose to report the weighted 
proportions. 
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4 ETHICAL CONSIDERATIONS 
 
4.1 REGISTER DATA 
 
Study  and V were based on non-identifiable register-based data and were approved by 
the ethical board in Stockholm (Dnr 2009/477-31/3).  
 
4.2 SNAC-K  
 
Study I and I were based on SNAC-Kungsholmen base-line data and were approved 
by the ethical board in Stockholm (Dnr 01-114). Informed consent was obtained for 
each participant. If the participant was unable to make an informed decision, a proxy 
consent was requested from a close relative. We only analyzed non-identifiable data. 
SNAC-K follows the ethical guidelines of the Swedish Council for Research in the 
Humanities and Social Sciences. 
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5 MAIN RESULTS 
 
5.1 STUDY I 
 
Institutionalized elderly used on average more drugs than home-dwelling elderly, i.e. 
7.2 compared to 4.3 drugs per person. PIDU was common in this nationwide study of   
1 260 843 home-dwelling and 86 721 institutionalized elderly. Thirty percent of the 
institutionalized and 12% of the home-dwelling elderly was exposed to at least one 
PIDU (Figure 4). The most common type of PIDU in institutions was concurrent use of 
three or more psychotropics. Among home-dwelling elderly, the most common type of 
PIDU was use of anticholinergic drugs. 
 
 
Figure 4 The prevalence of PIDU in 1 260 843 home-dwelling and 86 721 
institutionalized elderly in Sweden 2008. 
 
The crude logistic regression analysis revealed that institutionalization was associated 
with an increased likelihood of being exposed to overall PIDU. The association 
remained significant after adjustment for age and sex (data not shown) and after 
additional adjustment for number of drugs and the interaction terms (Table 6). Analyses 
of the individual indicators revealed that living in an institution was strongly associated 
with concurrent use of three or more psychotropic drugs, followed by anticholinergic 
drugs and long-acting benzodiazepines. On the contrary, institutionalization was 
associated with a lower probability of potentially serious DDIs, after adjustment for 
age, sex, number of drugs and the interaction terms. 
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Table 6. Adjusted odds ratios (ORs) and 95% confidence intervals (95% CIs) for potentially inappropriate drug use, overall, and stratified by age, 
2008 
 
Potentially 
Inappropriate drug 
use
a 
ORadj
b
 (95% CI) 
Anticholinergic drugs 
ORadj
b
 (95% CI) 
Long-acting 
benzodiazepines 
ORadj
b
 (95% CI) 
≥3 Psychotropics 
ORadj
b
 (95% CI) 
Potentially serious 
DDIs 
ORadj
b
 (95% CI) 
Age ≥65 years (n=1 347 564) 
Type of housing 
 
 
 
 
   Home-dwelling Ref Ref Ref Ref Ref 
  Institution 2.36 (2.29-2.44) 2.58 (2.48-2.68) 1.50 (1.41-1.60) 7.26 (6.96-7.56) 0.60 (0.55-0.65) 
 
Age < 80 years (n=885 430) 
Type of housing      
  Home-dwelling Ref Ref Ref Ref Ref 
  Institution 2.68 (2.54-2.83) 2.71 (2.53-2.90) 1.87 (1.68-2.08) 9.53 (8.89-10.21) 0.59 (0.51-0.68) 
Age ≥80 years (n=462 134) 
Type of housing      
  Home-dwelling Ref Ref Ref Ref Ref 
  Institution 1.80 (1.70-1.91) 1.76 (1.62-1.90) 0.83 (0.73-0.94) 6.75 (6.21-7.33) 0.48 (0.41-0.55) 
DDIs=drug-drug interactions; ORadj=adjusted odds ratio; 95% CI= 95% confidence interval 
a
Defined as exposure to at least 1 of the following indicators: use of anticholinergic drugs, use of long-acting benzodiazepines, concurrent use of ≥3 
psychotropics or potentially serious DDIs. 
b
Adjusted for age (continuous), sex, number of drugs (continuous) and the interactions between age and type of housing and between number of drugs 
and type of housing. 
 
2
6
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Analyses separated into younger elderly (aged <80 years) and older elderly (≥80 years) 
showed that institutionalization was positively associated with all types of PIDU in the 
younger elderly with the exception of potentially serious DDIs. In the older elderly, 
institutionalization was positively associated with overall PIDU, use of anticholinergic 
drugs and concurrent use of three or more psychotropics. However, institutionalization 
was associated with a lower likelihood of use of of both long-acting benzodiazepines 
and potentially serious DDIs among the older elderly (Table 6). 
 
Analysis of the persons using anti-dementia drugs (used as a proxy for dementia), 
revealed that use of these drugs was associated with a lower probability of exposure to 
overall PIDU compared to non-users of anti-dementia drugs (OR 0.89, 95% CI 0.86-
0.92), after adjustment for age, sex, type of housing and number of drugs. Analyses of 
the individual indicators showed that use of anti-dementia drugs was negatively 
associated with use of anticholinergic drugs (OR 0.83, 95% CI 0.79-0.87), long-acting 
benzodiazepines (OR 0.49, 95% CI 0.45-0.53) and potentially serious DDIs (OR 0.61, 
95% CI 0.56-0.66). However, use of anti-dementia drugs was positively associated with 
concurrent use of three or more psychotropic drugs (OR 1.45, 95% CI 1.38-1.51). 
 
5.2 STUDY II 
 
Of the persons with dementia, 46% used at least one analgesic drug compared to 25% 
of the persons without dementia. Sixty-three percent of the persons with dementia used 
at least one psychotropic drug compared to 32% of the persons without dementia. 
Persons with dementia used more opioids and paracetamol, but less NSAIDs than 
persons without dementia (Figure 5). In institutions, 49% used at least one analgesic, 
39% used paracetamol, 28% opioids, 3% NSAIDs and 73% at least one psychotropic 
drug. Among the home-dwelling elderly, 25% used at least one analgesic, 16% 
paracetamol, 8% opioids, 12% NSAIDs and 30% at least one psychotropic drug. About 
59% of the persons with dementia lived in institutions. 
 
Further analysis with logistic regression showed that persons with dementia had a 
higher probability of use of paracetamol (OR 1.99, 95% CI 1.22-3.26) and 
psychotropics (OR 2.47, 95% CI 1.59-3.83), whereas there were no significant 
differences in use of any analgesic (OR 1.38, 95% CI 0.87-2.19), opioids (OR 1.37, 
95% CI 0.73-2.56) and NSAIDs (OR 0.41, 95% CI 0.15-1.11), after controlling for age, 
sex, pain-related diagnosis, type of housing and the interactions between sex and 
dementia, age and dementia, pain-related diagnosis and dementia and between pain-
related diagnosis and type of housing. 
 
Results from the stratified analysis by dementia status showed that having at least one 
pain-related diagnosis was associated with a higher likelihood of use of analgesics in 
both persons with and without dementia (data not shown). Furthermore, having at least 
one pain-related diagnosis was significantly associated with use of any psychotropics, 
hypnotics and sedatives and antidepressants in persons with dementia but not in those 
without dementia (Table 7).  
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Figure 5. Use of analgesics and psychotropics in the study population (n=2 610), by 
dementia status. 
 
 
Table 7. Logistic regression for use of psychotropics 
in patients having a pain-related diagnosis compared to not  
having a pain-related diagnosis, stratified by dementia status   
Drug ORadj
a
 (95% CI) 
Dementia (n=304
b
)  
Any psychotropic 1.93 (1.16-3.21) 
Antipsychotics (N05A) 1.08 (0.48-2.43) 
Anxiolytics (N05B) 1.82 (0.90-3.69) 
Hypnotics and sedatives (N05C) 1.67 (1.02-2.74) 
Antidepressants (N06A) 2.60 (1.45-4.65) 
Non-dementia (n=2301
b
)  
Any psychotropic 1.14 (0.77-1.69) 
Antipsychotics (N05A) 0.60 (0.17-2.08) 
Anxiolytics (N05B) 1.28 (0.78-2.10) 
Hypnotics and sedatives  N05C) 1.47 (1.00-2.16) 
Antidepressants (N06A) 0.77 (0.48-1.25) 
a
adjusted for age, sex, MMSE score, residential setting, pain-related diagnosis and the 
interaction between  residential setting and pain-related diagnosis. 
b
five persons (1 with dementia and 4 without dementia) were not included in the analysis due 
to missing information about MMSE.  
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Table 8. Logistic regression for use of analgesics and psychotropic drugs, stratified by type of housing. 
 Any analgesics Opioids Paracetamol NSAIDs Any psychotropic 
 ORadj
a
 (95% CI) ORadj
a
 (95% CI) ORadj
a
 (95% CI) ORadj
b
 (95% CI) ORadj
a
 (95% CI) 
Home-dwelling 
 (n=2 318) 
     
Dementia status  
  Non-demented 
  Demented 
 
1 
1.00 (0.55-1.83) 
 
1 
0.78 (0.25-2.42) 
 
1 
1.36 (0.73-2.53) 
 
1 
0.45 (0.21-0.96) 
 
1 
1.43 (0.89-2.31) 
Pain-related diagnosis: 
  No 
  Yes 
 
1 
3.31 (2.22-4.94) 
 
1 
3.69 (2.03-6.70) 
 
1 
3.56 (2.25-5.63) 
 
1 
2.86 (2.17-3.78) 
 
1 
2.17 (1.48-3.18) 
Institution (n=292)      
Dementia status  
  Non-demented 
  Demented 
 
1 
1.80 (0.98-3.31) 
 
1 
1.31 (0.63-2.76) 
 
1 
2.40 (1.28-4.51) 
 
1 
1.18 (0.31-4.44) 
 
1 
2.83 (1.39-5.73) 
Pain-related diagnosis: 
  No 
  Yes 
 
1 
1.84 (1.39-2.96) 
 
1 
1.45 (0.84-2.49) 
 
1 
1.74 (1.05-2.90) 
 
1 
3.15 (0.78-12.7) 
 
1 
1.04 (0.61-1.75) 
a
adjusted for age, sex, dementia-status, pain-related diagnosis and the interactions between dementia and sex and dementia and pain related diagnosis. 
b
for NSAIDS the model were adjusted for the variables above except for sex among the institutionalized elderly and the interaction terms (since there 
were no mail NSAID users in the institutional setting and no non-demented NSAID users without pain-related diagnosis in the institutional setting).  
2
9
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Results from the stratified analysis by type of housing are presented in Table 8. There 
was no significant difference in the probability of use of any analgesics, opioids, 
paracetamol or any psychotropics among the home-dwelling elderly persons with and 
without dementia. However, dementia was associated with a lower use of NSAIDs in 
this setting. Among the institutionalized elderly, dementia was significantly associated 
with a higher use of paracetamol and any psychotropics. Having at least one pain-
related diagnosis was associated with a higher use of any analgesics, opioids, 
paracetamol, NSAIDs and psychotropics among the home-dwelling elderly, but only 
with use of any analgesics and paracetamol among the institutionalized elderly. 
 
5.3 STUDY III 
 
Of the persons with dementia, about 5% used osteoporosis drugs compared to 12% of 
the persons without dementia (Figure 6). Calcium/vitamin D combinations were the 
most commonly used osteoporosis drug in both persons with and without dementia.  
 
 
Figure 6. Use of osteoporosis drugs in the 305 persons with dementia and 2 305 
persons without dementia in SNAC-K. 
We found that persons with dementia were less likely to be treated with osteoporosis 
drugs, after controlling for age, sex, osteoporotic fractures and type of housing (own 
home or institution) (OR 0.34, 95% CI 0.19-0.59). Additional adjustment for 
educational level and use of glucocorticoids did not change the results.  
The lower probability of use of osteoporosis drugs among persons with dementia was 
not explained by low use among the severely demented persons since the results 
changed only marginally when these persons (i.e. persons with MMSE score <10) were 
excluded from the analysis (OR 0.32, 95% CI 0.17-0.60). 
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Persons with dementia had a higher prevalence of osteoporotic fractures the previous 
four years than persons without dementia, i.e. 25% compared to 7% (Figure 7). The 
most common osteoporotic fracture was hip fracture. However, after controlling for 
age, sex and for type of housing, there was no significant association between dementia 
and osteoporotic fractures (OR 1.35, 95% CI 0.92-1.99). Living in an institution was 
associated with osteoporotic fractures after controlling for age, sex and dementia status 
(OR 3.53, 95% CI 2.43-5.13). 
 
 
Figure 7. Prevalence of osteoporotic fractures the previous four years, by dementia 
status. 
5.4 STUDY IV 
 
By the date of 30 September 2008, 12 455 of the 1 347 564 analyzed individuals of age 
≥65 years used UTI antibiotics. The 1-day point prevalence for use of UTI antibiotics 
in Sweden was 1.6% among institutionalized and 0.9% among home-dwelling elderly. 
 
5.4.1 Women 
Among the institutionalized women treated with UTI antibiotics, trimethoprim was the 
most commonly used UTI antibiotic in both the younger and older ages (used by 31% 
and 40%, respectively). Among the home-dwelling women, the most commonly used 
UTI antibiotic was pivmecillinam in both age groups (i.e. used by 32% of the younger 
and 35% of the older home-dwelling women). 
 
The proportion of women treated with quinolones was higher in the younger ages, 
where 20% of the institutionalized women and 21% of the home-dwelling women used 
these drugs (Figure 8). According the national indicators,
104
 the proportion of women 
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using quinolones, of all women with lower UTI treated with UTI antibiotics, should be 
as low as possible. 
 
 
Figure 8. Proportion women treated with quinolones of all female UTI antibiotic users 
(n=8 538), 30 September 2008. 
 
The proportion of women treated with the recommended UTI antibiotics, i.e. 
pivmecillinam, nitrofurantoin or trimethoprim was 29%, 27% and 45% in institutions 
and 40%, 28% and 34% for home-dwellers, which is not consistent with the national 
goal (Figure 9). 
 
Of the women using UTI antibiotics, 2% (n=208) concurrently used anti-dementia 
drugs. Use of anti-dementia drugs (a proxy for dementia) was associated with a lower 
likelihood of use of quinolones (OR 0.57, 95% CI 0.36-0.89) after adjustment for age, 
type of housing and number of other drugs. There was no significant association 
between use of anti-dementia drugs and use of pivmecilliam (OR 1.15, 95% CI 0.85-
1.55), nitrofurantoin (OR 0.95, 95% CI 0.68-1.34) or trimethoprim (OR 1.13, 95% CI 
0.84-1.52). 
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Figure 9. The proportion of women treated with the recommended UTI antibiotics, i.e. 
pivmecillinam, nitrofurantoin or trimethoprim; goal
150
 and actual use in 
institutionalized and home-dwelling women, 30 September 2008.  
 
5.4.2 Men 
Among men, the most commonly used UTI antibiotic was a quinolone. This drug was 
used by 68% of the younger and 58% of the older home-dwelling men. In institutions, 
49% of the younger and 45% of the older men used quinolones. Also, the proportion of 
men treated with either trimethoprim or quinolones (which currently are the 
recommended drugs for treatment of UTI in men) was higher among home-dwelling 
men in age ≥80 years, where 83% of the home-dwelling men compared to 74% of the 
institutionalized men in the same age-group used these drugs (Figure 10).  
 
Among the male UTI antibiotic users, 2% (n=77) concurrently used anti-dementia 
drugs. There was no association between use of anti-dementia drugs and use of the UTI 
antibiotics (quinolones (OR 0.71, 95% CI 0.45-1.12), pivmecillinam (OR 1.19, 95% CI 
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0.56-2.51), nitrofuranotin (OR 0.96, 95% CI 0.45-2.02) or trimethoprim (OR 1.45, 95% 
CI 0.89-2.37). 
 
 
 
Figure 10. Proportion men treated with either quinolones or trimethoprim of all male 
UTI antibiotic users (n=3 917), 30 September 2008. 
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6 DISCUSSION 
 
6.1 MAIN FINDINGS 
 
6.1.1 Institutionalization and potentially inappropriate drug use 
We found that PIDU was more common in institutions than among home-dwelling 
elderly, which is in line with previous research.
78, 81, 96, 100, 103, 112, 172-173
 
Institutionalization was associated with use of overall PIDU and the specific indicators 
use of three or more psychotropics, anticholinergic drugs and long-acting 
benzodiazepines, but with a lower prevalence of potentially serious DDIs, after 
adjusting for age, sex and number of drugs. Few studies have so far compared PIDU 
between institutionalized and home-dwelling elderly.
80, 98, 107
 A recent study found no 
association between type of housing and overall risk of PIDU, although 
institutionalization was associated with some individual indicators, such as use of long-
acting benzodiazepines.
98
 A Canadian study found that the prevalence of PIDU 
declined after admittance to nursing home, although the number of drugs increased.
80
 
Another Canadian study found that institutionalized elderly were close to half as likely 
as home-dwelling elderly to be exposed to PIDU, after controlling for age, sex and co-
morbidities.
107
 Suggested explanations for these findings were mandatory service by 
clinical pharmacists in nursing homes in Canada
107
 and monitoring by health care 
professionals with experience of caring for older people.
80
 In Sweden, service by 
clinical pharmacists or other forms of medication reviews is currently not mandatory in 
institutions, which may affect the quality of drug use. However, we cannot exclude that 
the differences in findings are explained by differences in setting and criteria for PIDU. 
 
Furthermore, institutionalization was more strongly associated with PIDU among the 
younger elderly, which is in line with previous studies that have suggested that the 
younger elderly are at a high risk of PIDU.
57, 78, 87
 
 
Analysis of elderly persons treated with anti-dementia drugs (used as a proxy for 
dementia disease) showed that these persons on average had a higher quality of drug 
use compared to other elderly, with the exception of the individual indicator concurrent 
use of three or more psychotropics, which is in line with previous findings.
57
 A 
previous Swedish study reported that the quality of drug use was higher in nursing 
homes for dementia patients compared to other nursing homes, except for concurrent 
use of three or more psychotropic drugs.
57
 
 
6.1.2 Pain treatment and dementia  
We found that persons with dementia had a higher probability of use of paracetamol 
whereas there were no significant differences in use of any analgesic, opioids and 
NSAIDs, after adjustment for individual factors and type of housing (own 
home/institution). Our results contradict many previous studies, which have reported a 
lower use of analgesics among people with dementia compared to other elderly.
62, 174-175
 
However, Lövheim et al
130
 found results similar to ours, i.e. that persons with dementia 
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use more analgesics overall, in particular paracetamol, whereas there is no difference in 
use of opioids and NSAIDs. Their study was based on data from the GERDA/Umeå 
85+ study, which contain a sample of institutionalized and home-dwelling older people 
of age 85, 90 and 95 years and above living in Umeå, Sweden, and Vaasa and Mustaari, 
Finland. Also, a recent U.S. study measuring the use of analgesics in paracetamol 
equivalents, found that persons with dementia used significantly more analgesics than 
persons without dementia.
124 
 We found that paracetamol was the most commonly used 
analgesic in both persons with and without dementia, which seems reasonable given the 
high occurrence of muscosceletal pain-related conditions in old people.
125
 Also, the low 
use of NSAIDs in institutions and in persons with dementia may reflect a cautious 
prescribing of these drugs which are associated with an increased risk of 
gastrointestinal bleeding in older people.
176
 Taken together, these findings may reflect a 
change in pain management and treatment in persons with dementia. It has indeed been 
an increased focus on pain in persons with dementia over the last decades.
124, 177
 Also, 
the year 2006-2007 was announced as the global year against pain in older people by 
the International Association for the Study of Pain (IASP),
13
 although this occurred 
after the data collection of our study.  
 
However, many elderly persons may still lack adequate pain treatment.
13, 130, 178
 For 
example, Hartikainen et al
178
 found that although most home-dwelling older persons 
used analgesics, they still experienced daily pain both after movement and at rest. Thus, 
not only the presence of analgesics, but also the quality of analgesic treatment is 
important. A recent Swedish study showed that the prescriptions of opioids differed 
largely in hip fracture patients between different health care districts.
179
 Furthermore, 
persons in institutions and with dementia are often excluded from physical 
rehabilitation programs since they are often considered to be too frail to get beneficial 
effects,
180
 even though some studies suggest that cognitively impaired patient may 
benefit in physical functioning as much as other patients.
180-181
  
 
We also found that having a pain-related diagnosis was associated with use of any 
psychotropics, sedatives and antidepressants in persons with dementia, but not in 
patients without dementia. This could indicate that symptoms caused by pain may be 
inappropriately treated with psychotropics in patients with dementia,
68-69
 something that 
needs to be further investigated. Balfour et al
70
 found that AD patients with arthritis or 
rheumatism were undertreated with analgesics, whereas they were prescribed more 
benzodiazepines than AD patients without musculoskeletal conditions. However, in the 
treatment recommendations for BPSD published by the Swedish Medical Product 
Agency in 2008, pain is suggested as one factor that should be investigated before 
treatment with psychotropics are initiated.
52
 Also, a recent randomized clinical trial 
showed that treatment of pain in persons with dementia significantly reduced 
behavioral disturbances in these persons.
182
 Hopefully, further increased knowledge of 
pain behavior in persons with dementia will increase the appropriateness of pain 
treatment in this population.  
 
   37  
Like others, we found that use of analgesics was common in institutions.
6, 43
 However, 
having a pain related diagnosis was only associated with use of any analgesic and 
paracetamol in institutionalized elderly, but not with NSAIDs and opioids. This 
differed from the home-dwelling elderly, in that the presence of a pain-related 
diagnosis was also associated with use of opioids and NSAIDs in these persons. The 
associations were also weaker in the institutionalized elderly. It is possible that these 
results reflect an attempt to prevent pain, and eventually behavioral symptoms, in 
institutionalized elderly persons without a clear indication. If so, it is very important 
that the treatment effect is continuously monitored and evaluated, which is often not the 
case in practice in Swedish institutions.
74
 
 
6.1.3 Treatment of osteoporosis in persons with dementia 
Although osteoporotic fractures were more common in persons with dementia, the use 
of osteoporosis drugs was lower among these persons. The difference remained 
significant also after controlling for age, sex, osteoporotic fractures and type of 
housing. Moreover, our results were not explained by low use among persons with 
severe dementia. Few other studies have so far investigated the use of osteoporosis 
drugs in persons with dementia. However, our findings are in concordance with other 
studies that found that dementia/cognitive impairment was negatively associated with 
use of osteoporosis drugs.
65-66
 In contrast, cognitive impairment in osteoporosis patients 
was associated with use of osteoporosis drugs among home-dwelling elderly in a 
Canadian study.
183
  
 
We also found that the pattern of use of osteoporosis drugs differed between persons 
with and without dementia. It appears that calcium/vitamin D combinations were 
chosen before the more potent alternatives bisphosphonates and raloxifene in patients 
with dementia. However, bisphosphonates and raloxifene were relatively new drugs 
when the data of this study was collected. It is possible that fear of adverse side effects 
made the physicians select the more “safe” alternative calcium/vitamin D 
combinations. For example, patients with dementia may be more sensitive to serious 
adverse side effects of bisphosphonates and these drugs may also be complicated to 
administer in this population.
184
 Also, raloxifene is mainly used by postmenopausal 
women
185
 and lacks documentation of hip fracture prevention.
135
 Anyhow, our results 
suggests that persons with dementia are not only potentially undertreated for 
osteoporosis, but also that the treatment, when it occurs, is less potent. 
 
6.1.4 Use of urinary tract infection antibiotics in the elderly 
The analysis of indicators for treatment of lower UTI in women and men revealed that 
the Swedish national treatment recommendations were not adequately followed.  
 
We found that the use of quinolones (which should be as low as possible
104
) was high 
in both home-dwelling and institutionalized women, particularly in the younger ages 
(i.e. <80 years). The Swedish strategic program against antibiotic resistance 
(STRAMA) has, due to increased resistance levels, set the goal that the proportion of 
adult women treated for lower UTI with quinolones should not exceed 10% in ages <80 
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years.
186
 We found that this type of drug was about twice as common as the 
recommended level in ages 65-79 years. This finding is in line with the reported 
prevalence in younger Swedish women (i.e. 18-65 years of age).
163
 A high use in older 
ages may be of particular concern, since resistance levels may increase with age.
187
 
Quinolones are also frequently involved in adverse drug reactions and older people are 
in particular sensitive to adverse effects in the central nervous system.
104, 156
 Therefore, 
our finding that persons who used anti-dementia drugs were less likely to use 
quinolones seems reasonable given that dementia patients may be particularly sensitive 
to cognitive side effects. The use of quinolones in treatment of lower UTI may be 
overestimated in this study since quinolones also have other indications besides UTI, 
such as infected bedsores and pyelonephritis. However, if this is the case, it is 
surprising that the use of quinolones was less common in older ages, where such 
conditions are more common.
163, 188
 
 
Of the women treated with the recommended drugs, we found that the proportion of 
institutionalized women who used trimethoprim was 45%, i.e. much higher than the 
recommended 15-20%.
150
 Although the prescriptions for trimethoprim have generally 
decreased over the past ten years in Sweden,
156
 there was still a high use of 
trimethoprim in institutions in this study. In home-dwelling elderly, pivmecillinam was 
the most commonly used UTI antibiotic, which may reflect an implementation of the 
national guidelines for treatment of UTI in this group of women. Nitrofurantoin was 
used less commonly in both institutionalized and home-dwelling elderly than 
recommended by the Swedish guidelines (i.e. 27 and 28% of the institutionalized and 
home-dwelling women, respectively, were treated with this drug compared with the 
recommended level of 40%).
150
 Nitrofurantoin causes few ecological side effects and 
the resistance rate in uro-pathogens is low.
104, 189
 However, in patients with reduced 
kidney function, nitrofurantoin may be ineffective and may cause adverse side effects, 
such as partially reversible neuropathy.
190
 Therefore, our results may possibly reflect 
cautious prescribing of this drug in older people where reduced kidney function is 
common. However, a Swedish study found that nitrofurantoin accounted for only 14% 
of the prescriptions for UTI in women aged >18 years in outpatient care.
149
 This 
suggests that the low rate of prescriptions for nitrofurantoin may be a general problem 
and not only related to impaired kidney function in old age.  
 
In men, we found that quinolones, followed by trimethoprim, was the most commonly 
used UTI antibiotic, which is in concordance with Swedish guidelines.
104
 However, the 
proportion treated with either quinolones or trimethoprim was lower in institutionalized 
men, in particular in age ≥80 years. In this age group, we instead found a higher use of 
nitrofurantoin. Nitrofurantoin is not a recommended treatment for UTI in men since 
this drug doesn’t reach sufficient concentration in prostatic tissues and secretions.104, 191 
However, it is an ongoing discussion whether the treatment recommendations for UTI 
in men should be updated due to the increased resistance levels to trimethoprim and 
quinolones. 
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Similar to others, we found that the prevalence of use of UTI antibiotics was higher in 
institutions than among home-dwelling elderly.
148, 192
 Institutions are considered as a 
high risk environment for the development and spread of antibiotic resistance.
193-194
 
However, treating UTI in institutionalized elderly is often complicated by several 
factors. For instance, the symptoms may be diffuse and communication problems, 
mainly due to cognitive impairment, further complicates the diagnostics.
195
 Analysis of 
urine samples only have limited value in this population,
196
 since the prevalence of 
asymptomatic bacteriurea (ABU), which should not be treated with antibiotics, is 
high.
145
 ABU is an important factor to take into account when studying the quality of 
UTI treatment in the elderly population.
145
 
 
Unfortunately, since we lack information 
about diagnoses, we cannot estimate the occurrence of inappropriate treatment in ABU. 
However, although this limitation may affect the prevalence of use of UTI antibiotics in 
institutions, it would not affect the pattern of treatment, which is the main outcome 
measure in Study IV. 
 
6.1.5 Use of psychotropics in elderly people 
The findings in this thesis suggest that drug use in institutions was extensive, and often 
inappropriate for older people. In particular, the use of psychotropics was extensive, i.e. 
73% of the institutionalized elderly and 63% of the persons with dementia used at least 
one psychotropic drug (Study II). Almost one fifth of the residents in institutions were 
exposed to concurrent use of three or more psychotropics and persons with dementia 
were more likely to be exposed to this indicator (Study I). Extensive use of 
psychotropics in institutions and among persons with dementia has also been found in 
other studies.
57, 130
 This may be of concern as frail elderly people are particularly 
sensitive to adverse effects of these drugs, such as confusion and falls.
27, 58
 Moreover, 
the risk of adverse events increases when several of these drugs are combined.
197
 For 
the individual patient, use of three or more psychotropics may sometimes be justified. 
However, use of psychotropics in BPSD is often of limited value.
52
 Still, behavioral 
problems may have a greater impact on prescription of psychotropics than a psychiatric 
diagnosis in institutions.
198
 It is important that psychotropics are not prescribed in a 
routine-like manner due to insufficient elderly-care, including lack of staffing and 
education.
76
  
 
6.1.6 Undertreatment in elderly people 
We found that patients with dementia may be undertreated for osteoporosis (Study 
III). This finding illustrates that persons with dementia may be at risk of being 
undertreated for somatic conditions. For instance, previous research has shown that 
persons with dementia also are at risk of being undertreated for cardiovascular 
diseases and pain.
60-64 
 Efforts to avoid polypharmacy and adverse drug reactions, 
together with the risk that the dementia disease dominates the practitioner’s attention 
at the expense of other disorders, may lead to an underprescription of potentially 
valuable drugs.
34, 184, 199
 Another important cause may be communication problems. 
Husebo et al
60
 found that cognitively impaired institutionalized elderly receive fewer 
medications than cognitively intact persons. The authors suggested that this finding 
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may be due to cognitively impaired persons’ reduced ability to communicate their 
symptoms.
60
  
 
However, undertreatment of osteoporosis, and other conditions (e.g. cardiovascular 
diseases), also occurs frequently in other elderly persons. Previous studies have 
suggested that both elderly persons treated with many drugs, and elderly people with 
other chronic diseases than dementia, may be undertreated.
199-202
 A Dutch study 
found that older people with polypharmacy were more commonly exposed to 
undertreatment than other elderly persons.
202
 In that study, the most commonly 
underprescribed drugs were laxatives in patients treated with morphine followed by 
use of beta blocking agents in myocardial infarction and ACE-inhibitors in heart 
failure.
202
  
 
6.1.7 Improving drug use in older people 
Although undertreatment of several diseases is common among older persons, it is also 
common that drug therapies continue for a long time (many years) without a critical 
reevaluation of the effect.
4
  
 
Already in 2001, the Swedish government emphasized the importance of medication 
reviews in patients treated with many drugs in a proposal to the parliament.
4
 Several 
studies have shown that clinical pharmacy services may reduce the number of drug 
related problems (e.g. inappropriate drug use, adverse drug reactions and non-
adherence etc.),
203
 as well as morbidity and health care costs.
204
 Medication reviews are 
not currently mandatory in Swedish institutions, although it probably will be in the near 
future, according to a suggestion by the National Board of Health and Welfare.
205
 
However, the proportion of residents in institutions that have their medications 
reviewed has been suggested as an indicator for the evaluation of care and services in 
the elderly persons.
74
According to a recent report from the National Board of Health 
and Welfare, 66% of the institutionalized elderly had their medications reviewed in 
2010, although there were large differences between different municipalities ranging 
from 0-100%.
74
 A stressful situation, lack of time, staff and resources has previously 
been suggested as factors that complicates the implementation of medication reviews in 
many institutions.
4
 
 
Also, some practitioners may feel an uncertainty when treating frail elderly patients 
who use many drugs.
200, 206
 Practitioners may hesitate to follow evidence-based 
guidelines, since most guidelines are based on randomized controlled trials from which 
this population is excluded and which are not adapted for patients with 
multimorbidity.
200
 Therefore, there is a need for guidelines which also apply to frail 
elderly persons in institutions.
200
 However, since the disease pattern is often complex in 
these patients, an increased collaboration between general practitioners, specialist 
practitioners, nurses, clinical pharmacists and other health care professionals is 
necessary to keep the quality of drug use as high as possible. Also, time and resources 
should be allocated to facilitate the implementation of medication reviews in elderly 
people treated with many drugs. 
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6.2 LIMITATIONS 
 
6.2.1 Methodological considerations 
6.2.1.1 Study design 
The cross-sectional design of the studies in this thesis does not allow us to draw 
conclusions about causality. However in Study III, we analyzed the occurrence of 
osteoporotic fractures during four years before the use of drugs was recorded. 
 
6.2.1.2 Generalizability 
Representativeness, i.e. how well the sample reflects the target population, is important 
for the generalizability of the results in epidemiological studies.  
In Study I and IV, we analyzed the use of prescribed drugs in a large nationwide 
population of elderly persons. However, it is important to recognize that the study 
population only includes people who were dispensed at least one drug during the three-
month study period. Hence, we do not have any data on the non-users of prescribed 
drugs. Therefore, the healthiest elderly may not be represented in our register-based 
studies. In order to estimate the drug use on 30 September 2008, we assumed that all 
currently used drugs would be dispensed during the prior three months, since drugs are 
dispensed for a maximum of 90 days’ supply in Sweden. However, if the drugs were 
dispensed before the three-month period but used at a slower rate than intended, they 
would not be included in the analysis. Conversely, we might include drugs that were 
dispensed during the three-month period but discontinued prematurely.
79
  
 
The response rate in SNAC-K baseline (i.e. of those alive and eligible) was about 
73%. The reason for non-participation is unknown; but some basic characteristics 
were collected. There was no difference in the sex distribution between participants 
and non-participants, but the non-participants were on average slightly older, and 
therefore, probably more disabled and more likely to live in institutions.
51
 This might 
have led to an underestimation of drug use and diseases, particularly in the oldest 
patients. On the other hand, some non-participants, particularly those of younger age, 
were probably healthy persons who were not motivated to participate in a study about 
aging and health.
46
 Also, the participants in SNAC-K live in an urban area, a central 
part of Stockholm, and are on average relatively well educated.
207
 These factors may 
affect the generalizability of our results. In addition, the sampling proportions in the 
youngest and oldest age groups were larger than in the other age groups. However, 
since we weighed the data, this should not affect the generalizability of our results. 
 
6.2.1.3 Confounding 
In pharmacoepidemiological studies, it is important to consider confounding by 
indication, i.e. that the association between drug use and outcomes may be confounded 
by the underlying disease that the drug is indicated for.
208
 We have tried to handle this 
limitation in all of the studies. In study I and IV, we used number of drugs as a proxy 
for overall co-morbidity since we did not have information about diseases. In study II, 
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we analyzed the occurrence of pain-related diagnosis, and in study III, we analyzed 
osteoporotic fractures.  
 
Further, we took into account other major confounding variables available in our 
datasets (i.e. age, sex, dementia and type of housing). Additional adjustment for multi-
dose dispensing (i.e. ‘Apodos’) did not change the findings in Study I. Neither did 
adjustment for education or use of glucocorticoids in Study III. However, residual 
confounding due to unknown factors cannot be excluded. 
 
6.2.1.4 Other potential sources of bias 
6.2.1.4.1 Type of housing 
In Study I and IV, data about type of housing were retrieved from the Social Services 
register by the date of 30 June, 2008. All Swedish municipalities reported data about 
institutional care at that time point.
72
 However, it cannot be excluded that some 
mistakes have occurred during the data collection, e.g. some municipalities may have 
failed to report information for some individuals.
72
 
 
SNAC-K (Study II and III) has information about the different types of institutions. 
However, since some groups were small and we wanted to have enough statistical 
power, we chose to analyze the type of housing variable in the same way as in Study I 
and IV.  
 
6.2.1.4.2 Dementia 
In SNAC-K, the dementia diagnosis was clinically based, as neuroimaging or 
biomarkers were not available for the complete sample. However, the dementia 
diagnosis was set and validated according to the Diagnostic and Statistical Manual of 
Mental Disorders (4
th
 Edition) [DSM-IV] criteria
165
 in a three-step procedure; two 
physicians set the diagnosis independent of each other and in case of disagreement, a 
third expert was consulted to make the final diagnosis.
166
  
 
In Study I and IV, we used anti-dementia drugs as a proxy for dementia.
101
 Most 
patients who use these drugs have a dementia disorder (in particular AD), but all 
persons with dementia do not receive anti-dementia drugs. This leads to an 
underestimation of dementia, particularly other forms than AD. Also, it has been shown 
that high education is associated with use of anti-dementia drugs.
209
 Therefore, it is 
possible that we capture the more highly educated dementia cases in these studies. 
 
6.2.1.4.3 Other diseases/co-morbidities 
In Study I and IV, we did not have information about co-morbidities or indications for 
drug use. However, we used number of drugs as a proxy for overall co-morbidity.
167
  
 
In Study II, we chose not to study the participants’ experience of pain further since a 
high proportion of the persons with dementia were not able to answer questions about 
their experience of pain. Therefore, we constructed a variable for the occurrence of 
pain-related diagnoses. Information about these diagnoses was based mainly on self-
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report or information from a close relative. However, if the participant resided in an 
institution, this information was provided from medical records. The different sources 
of information could affect the reported prevalence of diseases in the different groups. 
For instance, the prevalence of pain-related disorders among home-dwelling elderly 
with dementia may have been underestimated, since relatives may not be aware of all 
the diseases/conditions of the participant.  
 
In Study III, we analyzed the occurrence of osteoporotic fractures retrieved from the 
Patient Register. Almost all fractures in Sweden are treated in hospitals and are thereby 
included in the register. Although we analyzed fractures known to be related to 
osteoporosis,
169
 some of them might have occurred in the absence of osteoporosis. 
However, due to the high age of the study population, we assume that most of the 
fractures were osteoporotic. 
 
6.2.1.4.4 Drug use 
The SPDR (Study I and IV) only contains information about prescription drugs 
dispensed at the pharmacy. Therefore, we lacked data on over-the-counter drugs, 
herbals, drugs used in hospitals and drugs supplied from drug store rooms in 
institutions, which may have led to an underestimation of drug use among home-
dwelling and institutionalized elderly, respectively. Also, dispensed drugs do not 
necessarily reflect the actual drug use, as adherence rates may be low.  
 
In Study II and III, information about drug use was retrieved from the participant or 
their relatives or from medical records, when the participant resided in an institution. 
The different sources of information could affect the reported prevalence of drugs in 
the different groups. Among the home-dwelling elderly, there is a risk of recall error. 
However, an advantage of using self-report is that the use of over the counter drugs 
(e.g. calcium/vitamin D combinations and minor analgesics) is taken into account. 
 
6.2.2 Other concerns 
The data about drug use in SNAC-K was collected in 2001-2004. Several new 
guidelines have been published since then, which may affect the use of drugs in older 
people. For instance, new recommendation about treatment of BPSD were published in 
2008 by the Swedish Medical Product Agency,
52
 which may have changed the use 
psychotropics in persons with dementia. 
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6.3 CONCLUSION 
 
We found that drug use was extensive among elderly Swedes, particularly among 
institutionalized elderly who used on average 7.2 prescribed drugs per person. 
About 30% of the institutionalized elderly and 12% of the home-dwelling elderly were 
exposed to at least one PIDU. Also, after controlling for age, sex and number of drugs 
(a proxy for co-morbidity), institutionalization was strongly associated with a higher 
probability of use of overall PIDU as well as the individual indicators use of 
anticholinergic drugs, long-acting benzodiazepines and concurrent use of three or more 
psychotropics. In particular, the high use of psychotropics may be of concern as frail 
elderly people are sensitive to adverse effects of these drugs e.g. confusion and falls. 
Therefore, there is a need for further research in order to investigate whether the higher 
occurrence of PIDU in institutions is explained by differences in disease patterns, 
different prescribing traditions or other underlying risk factors between these settings. 
 
Unlike many previous studies, we did not find that persons with dementia used fewer 
analgesics than other elderly. However, our results suggest that patients with dementia 
may be inappropriately treated with psychotropics for their pain. In addition, it seems 
that institutionalized elderly may receive analgesics regardless of the presence of a 
pain-related diagnosis. Therefore, there is a need for further investigations of the 
appropriateness of pain treatment in persons with dementia and institutionalized elderly 
persons. 
 
Although persons with dementia had a higher prevalence of osteoporotic fractures, they 
were less likely to use osteoporosis drugs than persons without dementia. Thus, our 
findings indicate an undertreatment of osteoporosis in persons with dementia.  
 
We found a different pattern of use of UTI antibiotics in institutionalized and home-
dwelling elderly persons. Our results indicate that the recommendations for treatment 
with UTI antibiotics were not adequately followed, which may lead to increased 
development of antibiotic resistance or unsuccessful treatment of the infection. In 
particular, the high use of trimethoprim (which is recommended as second line 
antibiotic for treatment of lower UTI in women) among institutionalized women and 
the low use of quinolones or trimethoprim (which currently are the recommended drugs 
in men) among institutionalized men need further investigation. Also the use of 
quinolones among the younger women was high.  
 
Taken together, the studies in this thesis show that older people are often exposed to 
inappropriate drug use, that undertreatment of important somatic diseases occur in 
persons with dementia, and that treatment recommendations may not be adequately 
followed in elder care. Our results indicate that elderly in institutions and those with a 
dementia disorder are particularly at risk of having poor quality of their drug therapy. 
Therefore, it is important that treatment guidelines and indicators also apply to these 
vulnerable groups. More attention should be given to older people's drug therapy, both 
in research and in practice. In order to improve the quality of drug use in elderly 
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people, time and resources should be allocated to facilitate the implementation of 
regular medication reviews in this population and the cooperation between different 
health care professionals should be encouraged. 
 
6.4 FUTURE DIRECTIONS 
 
Studies of drug use in the elderly population should be a continuous process. In the 
future, the number of elderly people will increase, new drug therapy will emerge and, 
hence, drug use will be even more important in this population. Therefore, the 
development and changes in drug therapy among older people should be monitored on 
a regular basis. This is particularly important for frail elderly persons in institutions and 
those with dementia. However, as many elderly people today continue to live in their 
own homes despite poor health, also these patients’ drug use needs to be regularly 
monitored and evaluated.  
 
The introduction of the new Social Services Register makes it possible, via record 
linkage to the SPDR, to nationally study drug use in the most frail elderly persons in 
institutions. This unique opportunity was utilized in this thesis, and should be further 
employed in future research. However, since the register also contains information 
about home-care services, also studies about drug use in frail home-dwelling elderly 
persons should be encouraged. 
 
Since the information about drug use in Study II and III in this thesis was collected in 
2001-2004, it is important that the results of these studies are complemented by results 
of studies with more recent data.  
 
Future studies of drug use should also aim to include diagnoses to limit the problem of 
confounding by indication. Then, it would be possible to observe actual differences in 
drug therapy between different groups (e.g. between institutionalized and home-
dwelling elderly) without the concern that the results are confounded by differences in 
the underlying disease patterns. 
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